PhotoPoint™ photodynamic therapy inhibits intimal hyperplasia in arteriovenous access grafts

Jennifer Barton, Heidi Nielsen, Steve Rychnovsky, Michael Farooq, Julie Freischlag, Robert Grove

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To evaluate the ability of PhotoPoint photodynamic therapy (PDT) to suppress venous anastomotic intimal hyperplasia (IH) in a canine prosthetic arteriovenous graft (AVG) model. Methods and materials: Bilateral femoral AVGs were placed in 12 mongrel dogs. PhotoPoint PDT was optimized by treating venous anastomoses with a fixed dose of photosensitizer (MV6401) followed by varying light doses. Veins were evaluated at 3 days for cell depletion. Other venous anastomoses received the optimal PhotoPoint PDT dose following graft placement and were harvested 1 month later. Histological sections of venous anastomoses were analyzed for intimal thickness, fibrosis, inflammation, necrosis and thrombosis. Results: PhotoPoint PDT resulted in a significant reduction of venous anastomotic intimal thickness. In addition, PhotoPoint PDT tended to reduce the development of fibrosis. All veins were patent at harvest, and there was no evidence of PhotoPoint PDT-related pathologies. Conclusions: PhotoPoint PDT significantly inhibited the development of venous anastomotic IH. These results suggest that PhotoPoint PDT is feasible and may increase patency rates of synthetic hemodialysis AVGs in the clinic.

Original languageEnglish (US)
Pages (from-to)147-151
Number of pages5
JournalCardiovascular Radiation Medicine
Volume3
Issue number3-4
DOIs
StatePublished - Jul 2002

Fingerprint

Tunica Intima
Photochemotherapy
Hyperplasia
Transplants
Veins
Fibrosis
Photosensitizing Agents
Thigh
Renal Dialysis
Canidae
Thrombosis
Necrosis
Dogs
Pathology
Inflammation
Light

Keywords

  • Arteriovenous grafts
  • Canine
  • Hemodialysis
  • Intimal hyperplasia
  • Photodynamic therapy
  • PhotoPoint
  • PTFE

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

PhotoPoint™ photodynamic therapy inhibits intimal hyperplasia in arteriovenous access grafts. / Barton, Jennifer; Nielsen, Heidi; Rychnovsky, Steve; Farooq, Michael; Freischlag, Julie; Grove, Robert.

In: Cardiovascular Radiation Medicine, Vol. 3, No. 3-4, 07.2002, p. 147-151.

Research output: Contribution to journalArticle

Barton, J, Nielsen, H, Rychnovsky, S, Farooq, M, Freischlag, J & Grove, R 2002, 'PhotoPoint™ photodynamic therapy inhibits intimal hyperplasia in arteriovenous access grafts', Cardiovascular Radiation Medicine, vol. 3, no. 3-4, pp. 147-151. https://doi.org/10.1016/S1522-1865(03)00081-7
Barton, Jennifer ; Nielsen, Heidi ; Rychnovsky, Steve ; Farooq, Michael ; Freischlag, Julie ; Grove, Robert. / PhotoPoint™ photodynamic therapy inhibits intimal hyperplasia in arteriovenous access grafts. In: Cardiovascular Radiation Medicine. 2002 ; Vol. 3, No. 3-4. pp. 147-151.
@article{8c9bcca766834f058a89460d28fee664,
title = "PhotoPoint™ photodynamic therapy inhibits intimal hyperplasia in arteriovenous access grafts",
abstract = "Purpose: To evaluate the ability of PhotoPoint photodynamic therapy (PDT) to suppress venous anastomotic intimal hyperplasia (IH) in a canine prosthetic arteriovenous graft (AVG) model. Methods and materials: Bilateral femoral AVGs were placed in 12 mongrel dogs. PhotoPoint PDT was optimized by treating venous anastomoses with a fixed dose of photosensitizer (MV6401) followed by varying light doses. Veins were evaluated at 3 days for cell depletion. Other venous anastomoses received the optimal PhotoPoint PDT dose following graft placement and were harvested 1 month later. Histological sections of venous anastomoses were analyzed for intimal thickness, fibrosis, inflammation, necrosis and thrombosis. Results: PhotoPoint PDT resulted in a significant reduction of venous anastomotic intimal thickness. In addition, PhotoPoint PDT tended to reduce the development of fibrosis. All veins were patent at harvest, and there was no evidence of PhotoPoint PDT-related pathologies. Conclusions: PhotoPoint PDT significantly inhibited the development of venous anastomotic IH. These results suggest that PhotoPoint PDT is feasible and may increase patency rates of synthetic hemodialysis AVGs in the clinic.",
keywords = "Arteriovenous grafts, Canine, Hemodialysis, Intimal hyperplasia, Photodynamic therapy, PhotoPoint, PTFE",
author = "Jennifer Barton and Heidi Nielsen and Steve Rychnovsky and Michael Farooq and Julie Freischlag and Robert Grove",
year = "2002",
month = "7",
doi = "10.1016/S1522-1865(03)00081-7",
language = "English (US)",
volume = "3",
pages = "147--151",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "3-4",

}

TY - JOUR

T1 - PhotoPoint™ photodynamic therapy inhibits intimal hyperplasia in arteriovenous access grafts

AU - Barton, Jennifer

AU - Nielsen, Heidi

AU - Rychnovsky, Steve

AU - Farooq, Michael

AU - Freischlag, Julie

AU - Grove, Robert

PY - 2002/7

Y1 - 2002/7

N2 - Purpose: To evaluate the ability of PhotoPoint photodynamic therapy (PDT) to suppress venous anastomotic intimal hyperplasia (IH) in a canine prosthetic arteriovenous graft (AVG) model. Methods and materials: Bilateral femoral AVGs were placed in 12 mongrel dogs. PhotoPoint PDT was optimized by treating venous anastomoses with a fixed dose of photosensitizer (MV6401) followed by varying light doses. Veins were evaluated at 3 days for cell depletion. Other venous anastomoses received the optimal PhotoPoint PDT dose following graft placement and were harvested 1 month later. Histological sections of venous anastomoses were analyzed for intimal thickness, fibrosis, inflammation, necrosis and thrombosis. Results: PhotoPoint PDT resulted in a significant reduction of venous anastomotic intimal thickness. In addition, PhotoPoint PDT tended to reduce the development of fibrosis. All veins were patent at harvest, and there was no evidence of PhotoPoint PDT-related pathologies. Conclusions: PhotoPoint PDT significantly inhibited the development of venous anastomotic IH. These results suggest that PhotoPoint PDT is feasible and may increase patency rates of synthetic hemodialysis AVGs in the clinic.

AB - Purpose: To evaluate the ability of PhotoPoint photodynamic therapy (PDT) to suppress venous anastomotic intimal hyperplasia (IH) in a canine prosthetic arteriovenous graft (AVG) model. Methods and materials: Bilateral femoral AVGs were placed in 12 mongrel dogs. PhotoPoint PDT was optimized by treating venous anastomoses with a fixed dose of photosensitizer (MV6401) followed by varying light doses. Veins were evaluated at 3 days for cell depletion. Other venous anastomoses received the optimal PhotoPoint PDT dose following graft placement and were harvested 1 month later. Histological sections of venous anastomoses were analyzed for intimal thickness, fibrosis, inflammation, necrosis and thrombosis. Results: PhotoPoint PDT resulted in a significant reduction of venous anastomotic intimal thickness. In addition, PhotoPoint PDT tended to reduce the development of fibrosis. All veins were patent at harvest, and there was no evidence of PhotoPoint PDT-related pathologies. Conclusions: PhotoPoint PDT significantly inhibited the development of venous anastomotic IH. These results suggest that PhotoPoint PDT is feasible and may increase patency rates of synthetic hemodialysis AVGs in the clinic.

KW - Arteriovenous grafts

KW - Canine

KW - Hemodialysis

KW - Intimal hyperplasia

KW - Photodynamic therapy

KW - PhotoPoint

KW - PTFE

UR - http://www.scopus.com/inward/record.url?scp=0142227744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142227744&partnerID=8YFLogxK

U2 - 10.1016/S1522-1865(03)00081-7

DO - 10.1016/S1522-1865(03)00081-7

M3 - Article

VL - 3

SP - 147

EP - 151

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 3-4

ER -